Update on Nephrogenic Systemic Fibrosis

Magnetic Resonance Imaging Clinics of North America

Volumn 16, Issue 4, 2008, Pages 551-560

  Thomsen, Henrik S ^a,b   Marckmann, Peter ^a   Logager, Vibeke B ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gadolinium based contrast agents; Late adverse reactions; Nephrogenic systemic fibrosis

Indexed keywords

CREATININE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

CHEMICAL REACTION; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DELAYED HYPERSENSITIVITY; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DISEASE REGISTRY; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; PATIENT ASSESSMENT; REVIEW; SKIN BIOPSY; SKIN DEFECT;

ADULT; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 52949102596     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2008.07.011     Document Type: Review

References (53)

1. Hammer F.D., Gofette P.P., Malaise J., et al. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 9 (1999) 128-136
2. Spinosa D.J., Matsumoto A.H., Hagspiel K.D., et al. Gadolinium-based contrast agents in angiography and interventional radiology. AJR Am J Roentgenol 173 (1999) 1403-1409
3. Gemmete J.J., Fortauer A.R., Kazanjian S., et al. Safety of large volume gadolinium angiography. J Vasc Interv Radiol 12 Part 2 (2001) S28
4. Marzaellla L., Blank M., Gelperin K., et al. Safety risks with gadolinium-based contrast agents. J Magn Reson Imaging 26 (2007) 816
5. Morcos S.K. Extracellular gadolinium contrast agents (Gd-CA): differences in stability. Eur J Radiol 66 (2008) 175-179
6. Thomsen H.S., Marckmann P., and Logager V.B. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7 (2007) 130-137
7. Greenen R.W.F., and Krestin G.P. Non-tissue specific extracellular MR contrast media. In: Thomsen H.S. (Ed). Contrast media. Safety issues and ESUR guidelines (2006), Springer, Heidelberg (Germany) 107-114
8. Dawson P. Gadolinium chelates: chemistry. In: Dawson P., Cosgrove D.O., and Grainger R.G. (Eds). Textbook of contrast media (1999), Isis Medical Media, Oxford (UK) 291-296
9. Desreux J.F., and Gilsoul D. Chemical synthesis of paramagnetic complexes. In: Thomsen H.S., Muller R.N., and Mattrey R.F. (Eds). Trends in contrast media (1999), Springer Verlag, Heidelberg (Germany) 161-169
10. Idee J.-M., Port M., Raynal I., et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563-576
11. Sherry A.D., Cacheris W.P., and Kuan K.-T. Stability constants for Gd3+ binding to model DTPA-conjugates and DTPA-proteins: implications for their use as magnetic resonance contrast agents. Magn Reson Med 8 (1988) 180-190
12. Harpur E.S., Worah D., Halz P.-A., et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection. A new magnetic resonance imaging contrast agent. Invest Radiol 28 Suppl 1 (1993) S28-43
13. Varadarajan J.A., Crofts S.P., Carvalho J.F., et al. The synthesis and evaluation of macrocyclic gadolinium-DTPA-bis(amide) complexes as magnetic resonance imaging contrast agents. Invest Radiol 24 Suppl 2 (1994) S18-S20
14. Watson A.D., Rocklage S.M., and Carvlin M.J. Contrast agents. In: Stark D.D., and Bradley Jr. W.G. (Eds). Magnetic resonance imaging. 2nd edition (1992), Mosby Year book, St. Louis (MO) 372-437
15. Cacheris W.P., Quay S.C., and Rocklage S.M. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 8 (1990) 467-481
16. Abraham J.L., Thakral C., Skov L., et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158 (2008) 273-280
17. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxoedema-like cutaneous disease in renal dialysis patients. Lancet 356 (2000) 1000-1001
18. Cowper S.E., Rabach M., and Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66 (2008) 200-207
19. Marckmann P., Skov L., Rossen K., et al. Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 69 (2008) 161-168
20. Tweedle M.F., Wedeking P., and Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30 (1995) 372-380
21. Todd D.J., Kagan A., Chibnik L.B., et al. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56 (2007) 3433-3441
22. Thomsen H.S., and Marckmann P. Extracellular Gd-CA: differences in prevalences of NSF. Eur J Radiol 66 (2008) 180-183
23. Rydahl C., Thomsen H.S., and Marckman P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium (Gd)-containing magnetic resonance contrast agent. Invest Radiol 43 (2008) 141-144
24. Cowper S.E. Nephrogenic systemic fibrosis. Adv Dermatol 23 (2007) 131-154
25. Stenver D.I. Pharmacovigilance: what to do if you see an adverse reaction and the consequences. Eur J Radiol 66 (2008) 184-186
26. Marckmann P., Skov L., Rossen K., et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3174-3178
27. Center for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56 (2007) 137-141
28. Broome D.R. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66 (2008) 230-234
29. Thomsen H.S. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17 (2007) 2692-2696
30. Kalb R.E., Helm T.N., Sperry H., et al. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 8 (2008) 607-610
31. Thomsen H.S., and Morcos S.K. Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum-creatinine be measured before contrast medium administration?. Eur Radiol 15 (2005) 749-754
32. Cockroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
33. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
34. Levey A.S., Greene T., Kusek J., et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 155A
35. Levey A.S., Coresh J., Greene T., et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53 (2007) 766-772
36. Bostom A.G., Kronenberg F., and Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13 (2002) 2140-2144
37. Stevens L.A., Coresh J., Greene T., et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
38. Band R.A., Gaieski D.F., Mills A.M., et al. Discordance between serum creatinine and creatinine clearance for identification of ED patients with abdominal pain at risk for contrast induced nephropathy. Am J Emerg Med 25 (2007) 268-272
39. Eken C., and Kilicaslan I. Differences between various glomerular filtration rate calculation methods in predicting patients at risk for contrast-induced nephropathy. Am J Emerg Med 25 (2007) 487 [Correspondance]
40. Prince M.R., Erel H.E., Lent R.W., et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 227 (2003) 639-646
41. Proctor K.A., Rao L.V., and Roberts W.L. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. Am J Clin Pathol 121 (2004) 282-292
42. Normann P.T., Frøysa A., and Svaland M. Interference of gadodiamide injection (OMNISCAN®) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest 55 (1995) 421-426
43. Choyke P.L., and Knopp M.V. Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. Radiology 227 (2003) 627-628
44. Morcos S.K., Thomsen H.S., and Exley C.M. Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast media: interaction with other drugs and clinical tests. Eur Radiol 15 (2005) 1463-1468
45. European Medicines Agency. Public assessment report, June 26th 2007. Available at:. www.esur.org Accessed December 22, 2007
46. Diego D.R. Nephrogenic system fibrosis: a radiologist's practical perspective. Eur J Radiol 66 (2008) 220-224
47. Kanal E., Barkovich A.J., Bell C., et al. ACR blue ribbon panel on MR safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 188 (2007) 1447-1474
48. Thomsen H.S., Marckmann P., and Logager V.B. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?. Acta Radiol 48 (2007) 593-596
49. High W., Ayers R.A., Chandler J., et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 27-30
50. White G.W., Gibby W.A., and Tweedle M.F. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41 (2006) 272-278
51. Rosky N.M., Sherry A.D., and Lenkinski R.E. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247 (2008) 608-612
52. Abraham J.L., and Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 66 (2008) 200-207
53. Thomsen H.S. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16 (2006) 2619-2621